Anupam Rasayan pledges subsidiary stakes to secure ₹300 crore debt

scanx
Reviewed by
Riya DScanX News Team
Key Highlights
  • Anupam Rasayan approves pledge of 100% stake in Mates Visa Consultancy to secure ₹300 crore NCD issuance
  • Parent company provides unconditional corporate guarantee for the subsidiary's debt obligations
  • Call option granted to Purebliss Pharma to purchase all MVCPL securities held by Anupam Rasayan
  • Separate pledge created over 15% stake in Purebliss Pharma to support its financing facilities
powered bylight_fuzz_icon
51204583

*this image is generated using AI for illustrative purposes only.

Anupam Rasayan India Ltd has approved the pledge of its entire stake in a wholly owned subsidiary and a partial stake in another associate to facilitate financing. The Board of Directors sanctioned these security documents on September 17, 2026, enabling debt issuance by its subsidiaries.

The primary transaction involves Mates Visa Consultancy Private Limited (MVCPL), a wholly owned subsidiary. MVCPL plans to issue up to ₹300 crore worth of senior secured unrated unlisted redeemable non-convertible debentures via private placement. Each debenture carries a face value of ₹1,00,000, with a maximum issuance of 30,000 units.

Security Structure

To secure these instruments, Anupam Rasayan will execute specific transaction documents:

  • A deed of pledge creating a first-ranking charge over 100% of the equity shares of MVCPL held by the parent company.
  • An unconditional corporate guarantee covering all amounts payable under the Mates Debenture Trust Deed.
  • A call option agreement granting Purebliss Pharma Solutions Private Limited the right to purchase all securities of MVCPL held by Anupam Rasayan on a fully diluted basis.

Additionally, the board approved a separate pledge over the company’s 15% stake in Purebliss Pharma Solutions Private Limited. This move supports financing facilities being availed by Purebliss. The pledge creates a first-ranking exclusive charge over these equity shares.

Execution Status

The finalisation and execution of these documents remain pending. The company will issue further disclosures to stock exchanges upon signing, as required under Regulation 30 of the SEBI Listing Regulations and Annexure 18 of the SEBI circular dated January 30, 2026. The board meeting commenced at 6:37 pm and concluded at 7:01 pm.

Historical Stock Returns for Anupam Rasayan

1 Day5 Days1 Month6 Months1 Year5 Years
+0.25%-3.93%-6.81%-6.81%-6.81%-6.81%

How will the ₹300 crore debt issuance impact Anupam Rasayan's overall leverage ratios and credit rating outlook?

What strategic rationale drives the pledge of 100% equity in MVCPL, and does this signal potential divestment or restructuring plans?

How might the call option granted to Purebliss Pharma Solutions influence future corporate governance or control dynamics within the group?

Anupam Rasayan board to consider ₹160 crore NCD issuance

scanx
Reviewed by
Riya DScanX News Team
Key Highlights
  • Board meeting scheduled for September 19, 2026, in Surat
  • Company to consider raising up to ₹160 crore via NCDs
  • Instruments will be secured, rated, unlisted, and redeemable
  • Issuance to be done through private placement basis
  • Intimation filed under SEBI Listing Regulations Regulation 29
powered bylight_fuzz_icon
51123910

*this image is generated using AI for illustrative purposes only.

Anupam Rasayan India Limited has scheduled a Board of Directors meeting for September 19, 2026, to consider raising capital. The company aims to raise up to ₹160 crore through the issuance of secured rated unlisted redeemable non-convertible debentures (NCDs) on a private placement basis.

The meeting will be held at the company’s registered office in Surat, Gujarat. This intimation was issued pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Fundraising Details

Parameter Details
Instrument Secured Rated Unlisted Redeemable Non-Convertible Debentures
Issue Size Up to ₹160 crore
Method Private Placement
Meeting Date September 19, 2026

The proposed fundraising is intended to strengthen the company’s capital structure. The board will deliberate on the terms and conditions of the issue during the scheduled meeting.

Regulatory Compliance

Anupam Rasayan filed the prior intimation with both the BSE Limited and the National Stock Exchange of India Limited on September 16, 2026. The disclosure confirms that the agenda includes the approval of the debt instrument issuance. No other material corporate actions were listed in the intimation.

The company secretary, Ashish Gupta, signed the disclosure, confirming compliance with listing regulations. The details are also available on the company’s official website.

Historical Stock Returns for Anupam Rasayan

1 Day5 Days1 Month6 Months1 Year5 Years
+0.25%-3.93%-6.81%-6.81%-6.81%-6.81%

How will the addition of ₹160 crore in secured debt impact Anupam Rasayan's debt-to-equity ratio and overall credit rating?

What specific operational expansions or working capital requirements is the company targeting with this private placement of NCDs?

How might the current interest rate environment in India influence the coupon rates offered to investors for these unlisted debentures?

More News on Anupam Rasayan

1 Year Returns:-6.81%